Genetic Analysis pens first pharma collaboration with US Rebiotix
OSLO--(BUSINESS WIRE)--Mdx specialist, Genetic Analysis AS (Genetic Analysis) today announced it has entered into a collaboration with US-based biotherapeutic company Rebiotix Inc. It is the first collaboration of its kind for GA in the growing microbiome-targeted therapeutics market. Genetic Analysis will provide its CE-marked GA-map™ dysbiosis test to Rebiotix to use in its research and development program.
“We are pleased to have reached an agreement with Rebiotix, which has been granted fast track status from the FDA for development of its first-in-class therapeutic product, RBX 2660. The agreement with Rebiotix represents a breakthrough for Genetic Analysis and recognition of the quality of our GA-map™ technology. We aim to build on this and see the US becoming a very important market for our test,” says Kari Stenersen, CEO of Genetic Analysis.
“Genetic Analysis, through the GA-map™ Dysbiosis test, enables Rebiotix to investigate potential new indications for our technology and to learn more about our current therapy. We are pleased to have signed an agreement with Genetic Analysis and look forward to working together,” said Rebiotix CEO Lee Jones.
About Genetic Analysis
Genetic Analysis has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås. www.genetic -analysis.com.
About Rebiotix
Rebiotix Inc. is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases, such as recurring Clostridium difficile infection, by harnessing the power of the human microbiome. The Roseville, MN, USA based company is pioneering practical and non-antibiotic treatments that reverse pathogenic processes and restore healthy gut flora through the transplantation of live microorganisms. For more information, visit www.Rebiotix.com.
Contacts
For further information, please contact:
CEO Kari Stenersen
Mobile: +47 48 32 16 20
E-mail: ks@genet-analysis.com
or
Media
Richard Hayhurst
Mobile: +44 7711 821 527
Email: Richard@richardhayhurstassociates.com
Help employers find you! Check out all the jobs and post your resume.
